Can we lower the chances of your acute myeloid leukemia (AML) growing by adding a drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your AML. The usual approach is defined as care most people get for AML.

To determine if patients that are 75 years of age or older who were recently diagnosed with DLBCL be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a cycle = 21 days; 4 cycles is 12 weeks) without significantly more side effects than patients taking the standard drug therapy alone; have longer, shorter, or the same amount of time without the disease getting worse (progression) than patients taking the standard drug therapy alone; live longer, live the same amount of time, or live a shorter amount of time than patients taking the standard drug therapy alone. This study is being done to find out if this approach is better or worse than the usual approach for the DLBCL. The usual approach is defined as care most people get for DLBCL.

Current treatments of Chronic ITP include Eltrombopag, Romiplostim, and Avatrombopag (DOPTELET). However, Doptelet provides unique benefits in that it can be orally taken as a pill once daily without restrictions on diet or requiring a provider unlike the other available treatments. This study aims to characterize the switch from other available treatments to doptelet and measure the safety, efficacy, and patient reported satisfaction with avatrombopag for 90 days.

This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).

The purpose of this study is to determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog-based ADT alone.

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

To develop an SCD Biochip with which to examine key cellular properties and interactions, including RBC and WBC cellular and adhesive properties, and circulating endothelial hematopoietic precursor cell characteristics. To correlate SCD Biochip function in heterogeneous SCD populations, including HbSS and HbSC at a range of ages, and in those with acute and chronic complications and compared with normal controls.

To understand how myeloma and its associated treatments affect the physical, cognitive (mental) health and overall well-being of an older adult, throughout the treatment/myeloma course.

To see if pomalidomide is an effective treatment for epistaxis in patients with HHT.

The purpose of this study is to understand why there are differences in outcomes in adolescents and young adults treated for ALL.